Intradermal/Sequential Allergy Testing Report

Report Title: Intradermal/Sequential Allergy Testing Report

Patient: [Full name], DOB: [Date of birth], MRN: [Medical record number]

Date of Testing: [Date]

Time: Start: [Start time]; Final read: [Final read time]

Location: [Clinic/site name]

Performing Clinician: [Name, credentials]

Interpreting Clinician: [Name, credentials] (If same as performing clinician, state "Same as above")

Indication: [Brief clinical question being addressed]

Pre-Test Clinical Context

• Relevant History:
  • Symptom pattern prompting testing: [Timing, severity, suspected triggers]
  • Prior allergy testing results: [Summary or "None" or "Not documented"]
  • Prior systemic reactions to testing or allergen exposure: [Summary or "None" or "Not documented"]
  • Comorbidities affecting risk/interpretation: [Asthma control status, dermatologic conditions, mast cell disorders, or "None"]
• Medication Screen:
  • Antihistamines/interfering medications withheld per protocol: [Yes / No / Partial - specify details]
  • Potential impact if not withheld: [Impact statement or "N/A"]
  • Beta-blocker use: [Present / Absent / Unknown]; risk mitigation: [Plan or "N/A"]
  • ACE inhibitor use: [Present / Absent / Unknown]; risk mitigation: [Plan or "N/A"]
• Baseline Assessment:
  • Vitals: HR [__], BP [__/__], RR [__], SpO₂ [__%] (If not obtained, state "Not obtained")
  • Respiratory status: [Stable / Cough / Wheeze / Increased work of breathing / Not assessed] (Include for patients with asthma or wheezing history)
• Consent: Informed consent obtained: [Verbal / Written per local policy / Not documented]

Test Methodology

• Test Type: [Intradermal single-dose / Sequential/incremental intradermal (dilutional) / Skin endpoint titration]; Protocol: [Standard clinic / Venom-specific / Drug-specific / Other]
• Controls: Positive control: [Agent, concentration]; Negative control: [Diluent type]. Controls placed concurrently with allergen testing.
• Allergen Extracts:

  Allergen (standardized name)	Manufacturer	Lot #	Expiration	Base concentration/units
  [Allergen name]	[Manufacturer]	[Lot #]	[MM/YYYY]	[Units]

• Dilution Schema: (Include only when sequential/incremental testing performed; otherwise omit)
  • Labeling method: [D1–D6 / 1:10 serial / BAU stepwise / Other]
  • Starting dilution and rationale: [Dilution and reason]
  • Step increment rule: [Increment description]
  • Interval between steps: [Minutes]
  • Maximum concentration planned: [Value and units]
• Technique: Test site(s): [Site(s) with laterality]; Injection volume: [Volume per test]; Read time: [Minutes]
• Measurement Method: Wheal recorded as [Largest diameter / Mean of orthogonal diameters]; Erythema [Measured / Not measured]; Positivity criteria: [Clinic-specific thresholds]

Procedure Notes

(Include only if procedure differed from standard protocol; otherwise omit this section entirely)

• Deviation: [Description]
• Justification: [Reason]

Results

Control Results

Control	Agent/Concentration	Wheal (mm)	Erythema (mm)	Validity
Positive	[Agent, concentration]	[__]	[__]	[Acceptable / Suboptimal / Invalid]
Negative	[Diluent]	[__]	[__]	[Non-reactive / Reactive]

(If controls are invalid, state that results may be uninterpretable)

Allergen Results – Intradermal (single-dose)

(Include only if single-dose intradermal testing performed)

Allergen	Concentration	Wheal (mm)	Erythema (mm)	Result	Comments
[Allergen name]	[Concentration]	[__]	[__]	[Positive / Negative / Equivocal]	[Technical issues or "None"]

Allergen Results – Sequential/Incremental (dilutional series)

(Include only if sequential/incremental testing performed)

Allergen	Dilution Step	Concentration	Wheal (mm)	Erythema (mm)	Result
[Allergen name]	[Step label]	[Concentration]	[__]	[__]	[Positive / Negative / Equivocal]

Endpoint Determination

(Include only when endpoint/threshold testing performed; otherwise omit)

• Endpoint definition used: [Clinic definition]
• Endpoint achieved: [Allergen and dilution/concentration, or "None achieved up to maximum concentration"]
• Confirmation at next stronger dilution: [Yes / No / N/A]

Interpretation

• Test Validity: [Interpretable / Limited / Not interpretable]; Controls acceptable: [Yes / No]; Limitations: [Medication interference / Dermatographism / Poor control response / Technical issues / None]
• Summary of Findings:
  • Positive responses: [List allergens and concentrations]
  • Negative responses: [List allergens tested]
  • Endpoints determined: [List or "N/A"]
• Clinical Correlation: [Narrative correlating results with patient history; distinguish sensitization from clinical allergy; acknowledge limitations; state if results guide immunotherapy or other treatment decisions; include recommended next steps as appropriate]

Safety and Adverse Events

• Monitoring: [Continuous / Intermittent]; Vitals rechecked: [Yes / No]; Symptoms during testing: [None / Description]
• Adverse Events: [None / Description including:]
  • Onset time: [Minutes post-injection]
  • Findings/symptoms: [Objective and subjective]
  • Interventions: [Medications with doses and timing]
  • Response: [Improved / Resolved / Persistent]
  • Escalation: [None / EMS / ED transfer / Other]
• Disposition: Observation duration: [Minutes]; Condition at discharge: [Stable / Other]; Post-test instructions including delayed reaction counseling: [Provided / Not provided]

Recommendations

(Include when results inform management; otherwise state "Interpretation communicated to ordering clinician; plan documented separately")

• Avoidance measures: [Recommendations or "None"]
• Medication adjustments: [Recommendations or "None"]
• Immunotherapy candidacy: [Candidate / Not candidate / Pending additional data]; Preliminary formulation guidance: [Details or "N/A"]
• Further testing: [Serum specific IgE / Supervised challenge / Repeat testing / Referral / None]
• Follow-up: [Timeline and responsible clinician]